Clarithromycin 250mg Capsules | Macrolide Broad-Spectrum Antibiotic

Clarithromycin 250mg Capsules | GMP Antibiotic Supplier
  • Dosage: Clarithromycin 250mg
  • Packaging: 10 capsules/blister*10/box
  • Shelf Life: 36months 

Click to add this item to cart.

Product Description

Product NameClarithromycin 250mg Capsules (Clarithromycin Oral Capsules)
SpecificationEach capsule contains: Clarithromycin 250mg
Dosage FormOral Hard Gelatin Capsule (for oral administration; swallow whole)
Active IngredientClarithromycin
Pharmacological ClassMacrolide Antibiotic (Bacterial Protein Synthesis Inhibitor)
Route of AdministrationOral administration (swallow whole with water). May be taken with or without food. Typically taken every 12 hours (twice daily), as directed by a healthcare professional.
PackagingBlister pack (PVC-Alu) or HDPE bottle, typically 10, 14, 20, or 100 capsules per blister pack or bottle
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Shelf Life36 months (unopened)

Product Overview

Clarithromycin 250mg Capsules is an oral antibiotic preparation containing Clarithromycin 250mg per hard gelatin capsule. Clarithromycin is a second-generation macrolide antibiotic with improved acid stability and broader tissue distribution compared to erythromycin. It is active against a wide range of Gram-positive and Gram-negative bacteria, as well as certain atypical pathogens.

Clarithromycin 250mg Capsules: What the Published Guidance Says

A broad portfolio spanning the WHO Access and Watch groups, supplied with the documentation that stewardship programmes and national tenders require.

This page collects the supply-relevant facts for Clarithromycin 250mg Capsules — specification, testing, packaging and the registration paperwork that travels with the batch.

  • Access group — the empirical workhorses The WHO AWaRe classification places amoxicillin, amoxicillin + clavulanic acid, ampicillin, clindamycin, gentamicin, metronidazole, chloramphenicol and doxycycline in the Access group. These are the medicines expected to be available in every functioning health system. WHO AWaRe (Access, Watch, Reserve) classification of antibiotics
  • AWaRe is the framework buyers and stewards now work to WHO's AWaRe classification divides antibiotics into Access, Watch and Reserve. Access agents are described as those that should be widely available, affordable and quality-assured to improve access and promote appropriate use. Watch agents carry higher resistance potential and should be prioritised as targets of stewardship programmes and monitoring. WHO Antibiotics Portal — AWaRe
  • WHO's own indication mapping is public — we align to it The WHO Antibiotics Portal lists amoxicillin as first choice for community-acquired pneumonia (mild to moderate), acute otitis media, acute sinusitis, acute pharyngitis and uncomplicated acute malnutrition in children; amoxicillin + clavulanic acid as first choice for severe community-acquired pneumonia in children, hospital-acquired pneumonia, cystitis and cellulitis; and ceftriaxone as first choice for severe acute pyelonephritis. WHO Antibiotics Portal — AWaRe

We quote these sources rather than paraphrase them loosely, because the detail matters commercially for Clarithromycin 250mg Capsules. Where your national list differs from the WHO listing, the national list governs what may be supplied and promoted locally.

Clarithromycin 250mg Capsules: Specification, Pack & Documentation Summary

Product NameClarithromycin 250mg Capsules (Clarithromycin Oral Capsules)
SpecificationEach capsule contains: Clarithromycin 250mg
Dosage FormOral Hard Gelatin Capsule (for oral administration; swallow whole)
Active IngredientClarithromycin
Pharmacological ClassMacrolide Antibiotic (Bacterial Protein Synthesis Inhibitor)
Route of AdministrationOral administration (swallow whole with water). May be taken with or without food. Typically taken every 12 hours (twice daily), as directed by a healthcare professional.
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Therapeutic groupAntibacterials — Antibacterials
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Ampicillin 500mg Capsules, Azithromycin 400mg Capsules, Amoxicillin 500mg Capsules, Lincomycin 250mg Capsules, Norfloxacin 100mg Capsules, Oxytetracycline 250mg Capsules, Ciprofloxacin 500mg Tablets, Amoxicillin Clavulanate 875/125mg Tablets.

How Clarithromycin 250mg Capsules Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Every batch of Clarithromycin 250mg Capsules is tested to the monograph stated on the purchase order. Where a monograph is silent on the presentation, we agree a written specification with you in advance and reference it on the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

  • Testing for related substances and impurities
  • Testing for dissolution or release profile (solid oral forms)
  • Testing for uniformity of dosage units
  • Testing for water content and pH where applicable
  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Clarithromycin 250mg Capsules Is Packed, Labelled and Shipped

  • Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 10, 14, 20, or 100 capsules per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
  • Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
  • Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
  • Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
  • Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Clarithromycin 250mg Capsules

Documents for Clarithromycin 250mg Capsules are issued by Sinophare Bio-technology Co., Ltd. — DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. Keeping one legal manufacturer across the COA, the GMP certificate and the registration file avoids assessment queries later.

  • Method validation, stability protocol and the shelf-life justification for the marketed pack.
  • Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
  • Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
  • Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
  • Batch manufacturing and packaging records released for inspection on request during supplier audits.

The context for Clarithromycin 250mg Capsules is its place among antibacterials classified in the WHO AWaRe framework. Listing status informs how programmes specify a product; it is not a substitute for the import licence or marketing authorisation of the destination country.

Questions We Are Asked About Clarithromycin 250mg Capsules

What pack size is available for Clarithromycin 250mg Capsules?

This presentation is normally supplied as Blister pack (PVC-Alu) or HDPE bottle, typically 10, 14, 20, or 100 capsules per blister pack or bottle. Where your market requires a different count, bottle or carton, we quote to your artwork and extend the stability file to the new pack.

What documentation comes with a shipment of Clarithromycin 250mg Capsules?

Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months.

Does the batch documentation for Clarithromycin 250mg Capsules support a registration filing?

Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

Do you supply amoxicillin + clavulanic acid in paediatric ratios?

We supply both the 400/57 mg chewable tablet and the 200/28.5 mg per 5 mL oral suspension presentations used in paediatric formularies.

How do you handle stewardship restrictions?

Watch-group orders are supplied against documented purchase requirements. We can provide AWaRe classification reference material to support your tender or formulary documentation.

Companion Products — Antibacterials

Browse the full Antibacterials range; all Capsules; the complete product catalogue.

Request a Quotation for Clarithromycin 250mg Capsules

For tenders and programme supply, send the line item, pack size, quantity and destination for Clarithromycin 250mg Capsules 250mg. We return a quotation with lead time, documentation list and sample availability in one response.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products